CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Genocea Biosciences Inc 's Total Debt to Equity

GNCA's quarterly Total Debt to Equity and Total Debt, Equity growth


In Spite of the debt repayement of -12.97%, in I Quarter 2022 ,Total Debt to Equity deteriorated to 0.62, below the Genocea Biosciences Inc 's average Total Debt to Equity.

Within Biotechnology & Pharmaceuticals industry in the first quarter 2022, 85 other companies have achieved lower Total Debt to Equity than Genocea Biosciences Inc in the I Quarter 2022. While Total Debt to Equity total ranking has deteriorated compared to the forth quarter 2021 from 1446 to 1950 .

Explain Debt to Equity Ratio?
What is the structure of GNCA´s Total Debt?
How valuable is the GNCA´s Equity?


GNCA Total Debt to Equity (Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity Change 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Total Debt Change -20.75 % -36.61 % -27.88 % -28.25 % -28.61 %
Total Debt to Equity MRQ 0.62 0.32 0.26 2.41 5.48
GNCA's Total Ranking # 1950 # 1446 # 129 # 431 # 2874
Seq. Equity Change -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Total Debt Change -12.97 % -11.34 % 1.37 % 1.33 % -30.39 %



Total Debt to Equity first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 86
Healthcare Sector # 331
Overall Market # 1950


Total Debt to Equity Statistics
High Average Low
5.48 1.03 0.12
(Mar 31 2021)   (Sep 30 2015)




Financial Statements
Genocea Biosciences Inc 's Equity $ 12 Millions Visit GNCA's Balance sheet
Genocea Biosciences Inc 's Total Debt $ 8 Millions Visit GNCA's Balance sheet
Source of GNCA's Sales Visit GNCA's Sales by Geography


Cumulative Genocea Biosciences Inc 's Total Debt to Equity

GNCA's Total Debt to Equity for the trailling 12 Months

GNCA Total Debt to Equity

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity TTM Growth 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Total Debt TTM Growth -20.75 % -36.61 % -27.88 % -28.25 % -28.61 %
Total Debt to Equity TTM 0.44 0.54 0.82 1.34 1.31
Total Ranking TTM # 2333 # 1810 # 655 # 588 # 274
Seq. Equity TTM Growth -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Total Debt TTM Growth -12.97 % -11.34 % 1.37 % 1.33 % -30.39 %


On the trailing twelve months basis Due to debt repayement of -12.97% Genocea Biosciences Inc decreased Total Debt to Equity in the 12 months ending in I Quarter 2022 to 0.44, below the company's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 59, during the past 12 months, other companies have achieved lower Total Debt to Equity than Genocea Biosciences Inc . While Total Debt to Equity total ranking has deteriorated during the twelve months ending in the I Quarter 2022, compared to the prior period, from 1810 to 2333.

Explain Debt to Equity Ratio?
What is the structure of GNCA´s Total Debt?
How valuable is the GNCA´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 60
Healthcare Sector # 441
Within the Market # 2333


trailing twelve months Total Debt to Equity Statistics
High Average Low
2.24 0.98 0.01
(Jun 30 2018)   (Dec 31 2016)




Companies with similar Total Debt to Equity in the quarter ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Total Debt to EquityMar 31 2022 MRQ Total DebtMar 31 2022 MRQ Equity
Oyster Point Pharma Inc   1.62 $ 90.636  Millions$ 55.993  Millions
Nanostring Technologies Inc   1.55 $ 225.511  Millions$ 145.305  Millions
Acorda Therapeutics Inc   1.43 $ 182.436  Millions$ 127.549  Millions
Gilead Sciences Inc   1.32 $ 26,208.000  Millions$ 19,915.000  Millions
Adma Biologics Inc   1.09 $ 138.423  Millions$ 126.933  Millions
Eloxx Pharmaceuticals Inc   1.04 $ 12.120  Millions$ 11.686  Millions
Evaxion Biotech A  0.95 $ 7.864  Millions$ 8.303  Millions
Axcella Health Inc   0.84 $ 25.118  Millions$ 29.892  Millions
Taysha Gene Therapies Inc   0.74 $ 37.386  Millions$ 50.725  Millions
Sorrento Therapeutics Inc   0.68 $ 153.027  Millions$ 226.198  Millions
Biogen Inc   0.65 $ 7,275.200  Millions$ 11,220.700  Millions
Outlook Therapeutics Inc   0.63 $ 22.781  Millions$ 35.963  Millions
Genocea Biosciences Inc   0.62 $ 7.647  Millions$ 12.385  Millions
Pluri Inc   0.57 $ 22.924  Millions$ 40.143  Millions
Rubius Therapeutics Inc   0.57 $ 76.377  Millions$ 134.649  Millions
Poseida Therapeutics Inc   0.56 $ 57.967  Millions$ 103.702  Millions
Qiagen N v   0.54 $ 1,861.450  Millions$ 3,466.611  Millions
Xtant Medical Holdings Inc   0.53 $ 15.451  Millions$ 29.283  Millions
Codiak Biosciences Inc   0.53 $ 25.514  Millions$ 48.379  Millions
Greenlight Biosciences Holdings Pbc  0.53 $ 33.535  Millions$ 63.826  Millions
Agenus Inc  0.51 $ 14.181  Millions$ 27.650  Millions
Applied Genetic Technologies Corporation  0.43 $ 20.428  Millions$ 47.027  Millions
Allena Pharmaceuticals Inc.  0.42 $ 4.893  Millions$ 11.616  Millions
Fennec Pharmaceuticals Inc   0.40 $ 4.989  Millions$ 12.524  Millions
Valneva Se  0.40 $ 97.824  Millions$ 246.173  Millions
Biomx Inc   0.37 $ 14.886  Millions$ 40.018  Millions
Eiger Biopharmaceuticals Inc   0.33 $ 31.995  Millions$ 97.267  Millions
Candel Therapeutics Inc   0.32 $ 20.525  Millions$ 63.762  Millions
Erytech Pharma S a   0.32 $ 8.453  Millions$ 26.305  Millions
Logicbio Therapeutics Inc   0.30 $ 7.515  Millions$ 24.911  Millions

Date modified: 2023-03-25T04:00:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com